Breaking

ImmunologyOral-Gut Immune Axis Proposed as Bidirectional Inflammation Model ● OncologyCLDN18.2 CAR-T Gains Potency With IP10 Armoring in Pancreatic Cancer ● OncologyPiggyBac PSR system enables stable SIN-retrovirus producer cells ● Critical CareGelsolin Levels May Help Predict Sepsis Mortality, Meta-Analysis Finds ● ImmunologyCalpains and T-cell quiescence: systematic review links proteolysis to tolerance ● ImmunologyTransAct TCR Stimulation Supports CD4 T Cells, Not CD8 T Cells ● OncologyPralsetinib in RET Fusion NSCLC After Immunotherapy: ARROW Sub-Analysis ● GastroenterologyPerceived stress linked to GERD screening in Palestinian medical students ●

ImmunologyOral-Gut Immune Axis Proposed as Bidirectional Inflammation Model ● OncologyCLDN18.2 CAR-T Gains Potency With IP10 Armoring in Pancreatic Cancer ● OncologyPiggyBac PSR system enables stable SIN-retrovirus producer cells ● Critical CareGelsolin Levels May Help Predict Sepsis Mortality, Meta-Analysis Finds ● ImmunologyCalpains and T-cell quiescence: systematic review links proteolysis to tolerance ● ImmunologyTransAct TCR Stimulation Supports CD4 T Cells, Not CD8 T Cells ● OncologyPralsetinib in RET Fusion NSCLC After Immunotherapy: ARROW Sub-Analysis ● GastroenterologyPerceived stress linked to GERD screening in Palestinian medical students ●

Advertisement

RM

Dr. Revathy Mohan V.R., MBBS

Active Clinical Contributor & Author

Clinical Articles & Analysis by Dr. Revathy Mohan V.R., MBBS

1283 Articles

mTORC1-TFEB activation linked to hepatocellular carcinoma aggressiveness

A JCI Insight study examines noncanonical mTORC1-TFEB signaling in hepatocellular carcinoma and its role in hepatocyte plasticity and…

PARP inhibitors in breast cancer: expanding use beyond BRCA1/2

A JCI review examines PARP inhibitors beyond BRCA1/2-mutated breast cancer, focusing on HRD biology, biomarkers, and combination strategies.

Oncology·Endocrine

PPGL treatment algorithm adds molecular guidance to metastatic care

MD Anderson’s PPGL algorithm ties molecular subtype and progression rate to systemic therapy choices, including belzutifan and radioligand…

Independent Review Board

All articles authored by our clinical fellows are cross-audited by MWF Review Team featuring 10 senior department chairs from premier hospitals.

Explore Review Team

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.

Advertisement

Most Read

Medicine World Foundation Alerts

Daily Clinical Dispatch

Receive peer-screened summaries across 17 clinical specialties delivered to your inbox every morning.

Trending Topics Clinical Keywords

#GLP-1 #Lecanemab #CAR-T #SepsisBundle #Semaglutide #SGLT2 #LongCOVID #AntibioticStewardship #AIDiagnostics #Statins

Advertisement

Advertisement